Monday, January 13, 2014
FutuRx Incubator, formerly BioBoost, which has been granted a license by Israel’s Ministry of Economy to establish a biotech incubator in Israel, began operations Jan. 1 at the Weizmann Science Park in Ness Ziona. Thirty to 40 startup companies are planned to be established during the next eight years. FutuRx was incorporated jointly by OrbiMed Israel Partners, Johnson & Johnson Innovation and Johnson & Johnson Development (JJDC) and Takeda Pharmaceutical through its corporate venture arm Takeda Ventures.
OrbiMed, a global investment management firm focused on the healthcare sector, has closed its first investment fund dedicated to life sciences venture capital opportunities based in Israel. The Fund, OrbiMed Israel Partners Limited Partnership, includes an anchor investment provided by the government of Israel, which also provided special economic terms through the initial tender process for the Fund.
OrbiMed, an investment management firm focused on the healthcare sector, has reported the final closing of a new fund that acquires healthcare royalty streams and provides structured debt capital to healthcare companies. The fund, the “Royalty Opportunities S.ar.l.,” is domiciled in Luxembourg and will invest worldwide to take advantage of OrbiMed’s global platform. Investors in the $600 million fund include some of the largest endowments, foundations and financial institutions globally.